In an interview with <em>Targeted Oncology</em>, Ian W. Flinn, MD, PhD, discussed the findings from the phase III BRIGHT trial for patients with MCL. He also highlighted the impact of BR in this patient population and other combinations under active investigation.
Myung-Ju Ahn, MD, discusses the results from the AURA LM trial and the next steps that need to be taken in order to confirm the efficacy that was seen with the lower dose. In addition, she highlights where research in the treatment landscape of advanced NSCLC is headed.
In an interview with <em>Targeted Oncology</em>, Banu Arun, MD, discussed the role of genetic testing in patients with metastatic breast cancer. She highlighted the importance of identifying various mutations, including <em>BRCA1/2 </em>mutations in light of the approval of PARP inhibitors. In addition, she spoke to how the role of genomic testing is evolving in this field with the development of new targeted agents.
Jacqueline C. Barrientos, MD, MS, discusses the emerging treatment options for patients with CLL, as well as some of the other strategies being looked at in clinical trials.
Nicolas Girard, MD, discussed the importance of evaluating durvalumab in a real-world setting. In addition, he highlights other questions that remain unanswered in this area, as well as the role of immunotherapy in patients with NSCLC.
R. Michael Tuttle, MD, discusses the outcomes from a 2-day interactive meeting which brought together thryoid cancer experts across 4 organizations and 8 countries to discuss the use of radioactive iodine therapy, including the development of 9 principles for the optimal management of patients.
Andre Goy, MD, highlighted major controversies being investigated in the field of MCL in terms of patient subgroups and optimal management of each subpopulation.
In an interview with Targeted Oncology, Alexander E. Perl, MD, discussed the final results from the ADMIRAL trial and the impact these results have on practice.
A look back at all the FDA news that happened in the month of April 2019, including several new approvals, a priority review, breakthrough designation, and more.
Maria E. Cabanillas, MD, discusses some of the ongoing thyroid cancer clinical trials at The University of Texas MD Anderson Cancer Center, as well as other promising research on the horizon across all subtypes of the disease.
Aditya Bardia, MBBS, MPH, discusses the potential role of circulating tumor cells and circulating tumor DNA testing in patients with breast cancer.
David Goldenberg, MD, FACS, discusses possible risk factors associated with thyroid cancer, including a retrospective analysis that looked at the effect of radiation exposure.
William G. Wierda, MD, PhD, discussed the emerging role of small molecule combinations and fixed-duration treatments in patients with relapsed/refractory CLL.
Richard M. Stone, MD, discusses the emerging agents for older patients with AML, as well as the importance of patient assessment and the identification of select mutations.
Analyses from the phase III ARIEL3 trial presented during the 2019 Society of Gynecologic Oncology Annual Meeting showed that rucaparib is safe and effective as a maintenance therapy across all subgroups of patients.
In an interview with <em>Targeted Oncology, </em>David O’Malley, MD, discussed the updates with bevacizumab and PARP inhibitors as a treatment and maintenance therapy option for patients with ovarian cancer and recurrent disease. He also discussed considerations for selecting the right agent for the right patient.
A look back at all the FDA news that happened in March 2019, including several new approvals, a clinical hold, an orphan drug designation, and more.
Gynecologic oncology experts reflect on some of the most significant data presented during the 2019 SGO Annual Meeting, which underscored how the field is moving toward a precision medicine approach.
Radiation oncologist Jimmy J. Caudell, MD, PhD,discusses the role of radioactive iodine therapy in patients with DTC. He also highlights areas of research that may help determine the best treatment regimens and doses for select patients.
Thomas W. Flaig, MD, discusses the latest updates to the NCCN guidelines for the treatment of patients with muscle-invasive bladder cancer. In addition, he highlights the latest approvals of checkpoint inhibitors in this patient population.
Carla Casulo, MD, discusses challenges in the management of patients with relapsed/refractory follicular lymphoma and progress being made toward predicting early relapse in these patients.
Sarah Rutherford, MD, discusses a pilot study at Weill Cornell Medicine investigating ribavirin as a treatment for patients with follicular lymphoma.
Ahead of the 50th Annual SGO Meeting, Shannon Westin, MD discussed the key takeaways from a case chat and highlighted some data she is looking forward to at the meeting for patients with recurrent ovarian cancer. She also highlighted other data that will play an important part in this treatment landscape and for patients with recurrent cervical cancer.
Paul J. Shaughnessy, MD, discusses updates in stem cell mobilization and transplant for DLBCL, including the potential for CAR T-cell therapy to supplant autologous stem cell transplant.
Sagar Lonial, MD, discussed some of the emerging agents for the treatment of patients with late relapse in multiple myeloma.
Andre Goy, MD, discusses some of the recent changes that have been seen in the treatment landscape for patients with MCL and some of the ways these subsets of patients are being identified in order to find the best treatment option for an individual patient.
Jean-Jacques Kiladjian, MD, PhD, discusses 2 clinical trials evaluating the use of ruxolitinib in patients with polycythemia vera and myelofibrosis.
Hope Rugo, MD, discusses results from a trial that evaluated a reduced dose of palbociclib in patients with HR+ metastatic breast cancer. She also shares details from research for a scalp cooling cap to reduce hair loss for patients with breast cancer.
A look back at all the FDA news in oncology from the month of February 2019, including several new approvals, priority review designations, and an orphan drug desgination.
Lori J. Wirth, MD, discusses the current treatment options for patients with advanced thyroid cancers, in addition to some of the trials that are currently enrolling at her center. She also highlights early data that have been presented for targeted therapies in advanced thyroid cancer.